Trial Summary
What is the purpose of this trial?
To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.
Research Team
XJ
Xiao Jing (Iris) Wang, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for adults with a BMI of 18-35 who suffer from functional dyspepsia, commonly known as indigestion. Participants must be able to consent and not have other conditions that could affect the study's results. Those with recent alcohol or substance use disorders, current H. pylori infection, or who are pregnant or nursing cannot join.Inclusion Criteria
Body Mass Index (BMI) of 18-35 kg/m2
Able to provide written consent
I don't have other health conditions that could affect the study's outcome.
Exclusion Criteria
Current H. pylori infection
Pregnancy or nursing
Recent history of Alcohol Use Disorder or Substance Use Disorder
Treatment Details
Interventions
- Placebo (Drug)
- Tradipitant (Neurokinin-1 Receptor Antagonist)
Trial OverviewThe trial is testing Tradipitant against a placebo to see if it improves gastric functions and reduces symptoms like feeling full quickly (satiation) and discomfort after eating in people with indigestion.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TradipitantExperimental Treatment1 Intervention
Oral Capsule
Group II: PlaceboPlacebo Group1 Intervention
Oral Capsule
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xiao Jing (Iris) Wang
Lead Sponsor
Trials
1
Recruited
60+
Vanda Pharmaceuticals
Lead Sponsor
Trials
68
Recruited
19,900+
Mayo Clinic
Collaborator
Trials
3,427
Recruited
3,221,000+
Dr. Gianrico Farrugia
Mayo Clinic
Chief Executive Officer since 2019
MD from University of Malta Medical School
Dr. Richard Afable
Mayo Clinic
Chief Medical Officer
MD from Loyola Stritch School of Medicine